Ipilimumab Biosimilar - Research Grade

Product Specifications

Background

Ipilimumab biosimilar is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab biosimilar is an IgG1 kappa immunoglobulin with an approximate molecular weight of 148 kDa. Ipilimumab biosimilar is produced in mammalian (Chinese hamster ovary) cell culture.

Specifications

Detects human CTLA-4. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Ipilimumab.

Product Name Alternative

Ctla4, Cytotoxic T-lymphocyte protein 4, CD152

UniProt

P16410

Host

Humanized

Species Reactivity

Human

Target

CTLA-4

Purification Method

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Concentration

1.0 - 5.0 mg/mL

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>95% by SDS-PAGE and HPLC

Buffer

ICH3001-100mL ICH3002-100mL ICH3003-100mL

Shipping Conditions

Blue ice

Storage Conditions

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.